Evidence map›Paper›PMID 32983494›Full record

ArticleClinical case reports2020

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count.

Marion Divoux, Alexia Plocque, Margaux Sevin, Laurent Voillat, Pierre Feugier, Agnès Guerci-Bresler, Francois Girodon, Julien Broséus

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Marion DivouxUniversité de Lorraine, CHRU-Nancy, Service d'Hématologie Clinique, Pôle Spécialités Médicales, France Nancy France.ORCID https://orcid.org/0000-0002-5946-311X
Alexia PlocqueHaematology Laboratory University Hospital Dijon France.
Margaux SevinInserm U1231 University of Bourgogne Franche-Comté Dijon France.
Laurent VoillatHaemato-Oncology Department Hospital of Chalon-sur-Saône Chalon-sur-Saône France.
Pierre FeugierUniversité de Lorraine, CHRU-Nancy, Service d'Hématologie Clinique, Pôle Spécialités Médicales, France Nancy France.
Agnès Guerci-BreslerUniversité de Lorraine, CHRU-Nancy, Service d'Hématologie Clinique, Pôle Spécialités Médicales, France Nancy France.
Francois GirodonHaematology Laboratory University Hospital Dijon France.ORCID https://orcid.org/0000-0003-3151-1068
Julien BroséusUniversité de Lorraine, CHRU-Nancy, Service d'Hématologie Biologique, Pôle Laboratoires, France Nancy France.ORCID https://orcid.org/0000-0002-6689-4006
Université de Lorraine · FRInserm · FRMaison des Sciences sociales et des Humanités de Dijon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN-RS-T in the context of major platelet counts.

Indexed as

lenalidomidemyelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosismyelodysplastic syndromemyeloproliferative syndromethrombocytosis

Identifiers

PMID32983494
PMCPMC7495870
OpenAlexW3034738523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.